Eurofins Reinforces Its Specialty Clinical Diagnostics Footprint by Entering into a Joint Venture with Emory University to Fu...
2015年6月29日 - 2:30PM
ビジネスワイヤ(英語)
Regulatory News:
Eurofins (Paris:ERF):
Eurofins Scientific (EUFI.PA), the global leader in
bio-analytical testing, and one of the world leaders in genomic
services, announces that it has signed an agreement to acquire a
75% stake in Emory Genetics Laboratory (“EGL”) from Emory
University’s School of Medicine for approximately US$ 40m in cash,
subject to standard closing adjustments.
EGL provides high-complexity molecular, biochemical and
cytogenetic testing for rare and common genetic diseases and
disorders. Founded in 1970, EGL employs around 100 staff at its
laboratory in Atlanta, GA, and serves over 400 institutional
clients (hospitals and other commercial laboratories) across the
US. It expects to generate revenues in excess of US$ 15m for
2015.
EGL is renowned for testing rare genetic disorders. The
laboratory has comprehensive testing facilities for cytogenetic,
biochemical and molecular genetics. As the first academic
laboratory to bring Next Generation Sequencing (NGS) technologies
to the commercial clinic market, EGL remains a leading player in
cutting-edge genetic tests, with “first-to-market” tests comprising
more than 80% of its analytical portfolio. As a leading NGS testing
laboratory, EGL believes it has the largest menu of NGS panels in
the industry, and conducts over 35,000 tests annually for genetic
diseases, carrier screening, as well as prenatal testing.
Furthermore, EGL is leading the industry in gene panels including
cancer testing and exome sequencing, to aid diagnosis, prognosis,
management and targeted drug therapy (e.g., personalized medicine),
in addition to expanded carrier testing capabilities.
EGL’s competencies advance Eurofins’ footprint in the genetics
and genomic segment of the specialty clinical diagnostic testing
market. Its expertise in genetic diseases and cancer testing fully
complements Eurofins leading position in infectious diseases,
achieved through the acquisition of ViraCor-IBT and Diatherix, and
in cardiovascular diseases with that of Boston Heart. With this
acquisition of EGL, Eurofins further strengthens both its
pharmaceutical and genomic service offering and reinforces its
development into a leading presence in the specialty clinical
testing services for hospitals, clinicians and pharmaceutical
companies. Post-closing, the company will be known as EGL Genetic
Diagnostics, LLC, a joint venture company of Eurofins and Emory
University.
Comment from Dr. Madhuri Hegde, Executive Director, EGL:
“The team at Emory Genetics Laboratory is excited about working
with Eurofins, contributing our unparalleled expertise in clinical
diagnostics, and expanding the reach of our experience to an
international patient community. Our team of more than 100 staff
members is led by a highly experienced and knowledgeable team of
laboratory directors who are pioneers in the field of human
genetics.”
Comment from Dr. Gilles Martin, Eurofins CEO: “This joint
venture with world-renowned medical and scientific teams at Emory
University strengthens Eurofins’ growing footprint in the specialty
clinical diagnostics market, and provides the Group a truly unique
platform to leverage its renowned competence in genomic testing to
better serve the global healthcare community. In combination with
ViraCor, Boston Heart and Diatherix, EGL provides Eurofins a
leading position in the most technologically-driven segment of the
specialty clinical diagnostic testing market.”
For more information about Eurofins, please visit
www.eurofins.com
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With over 17,000 staff in more than 200 laboratories across 36
countries, Eurofins offers a portfolio of over 130,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results on time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the Euronext
Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg
ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantee can be made as to their validity.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150628005081/en/
Eurofins Scientific GroupInvestor Relations, +32 2 766
1620ir@eurofins.com
Enerplus (NYSE:ERF)
過去 株価チャート
から 6 2024 まで 7 2024
Enerplus (NYSE:ERF)
過去 株価チャート
から 7 2023 まで 7 2024